Clinical Commander

Back to dossier
cardio.acute-hf.viral-cardiomyopathy-decompensation.v1PRODUCTION
cardio.acute-hf.viral-cardiomyopathy-decompensation.v1

Acute HF — viral cardiomyopathy / myocarditis decompensation (non-shock)

cardiologyacuteadult
Hard-required inputs
0 / 8
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Viral cardiomyopathy / myocarditis ADHF (non-shock): viral injury → LV dysfunction + congestion; supportive ADHF management; standard GDMT cautiously; AVOID NSAIDs; identify etiology-altering subsets (giant cell, eosinophilic, sarcoid → separate dossiers); recovery possible especially parvovirus

Inputs
1
Actions
0
Advance rule
Set
Advance when

viral myocarditis ADHF framed

Patient inputs (11)

Acute viral myocarditis disproportionately affects younger adults (20–50); chronic DCM from remote viral myocarditis spans all ages; pediatric fulminant cases route to peds-specific dossier

Recent (within 4 wk) viral prodrome suggests acute myocarditis; remote myocarditis history suggests chronic DCM decompensation; both spectrums have different prognosis + treatment timelines

eGFR for diuretic + GDMT dosing (ARNI, MRA, SGLT2i thresholds); LFTs for congestive hepatopathy + statin safety

LV systolic function (regional vs global hypokinesis), RV involvement, pericardial effusion (myopericarditis common), LV thrombus screen if severe dysfunction; serial echo for recovery monitoring

Elevated in active myocarditis (released from injured myocytes); persistent elevation >2 wk portends worse outcome (ESC 2013 Caforio); peak proportional to injury extent

Marker of HF severity; titrate diuresis; trend during admission for response monitoring

ECG abnormalities in 85%+ of myocarditis (any T-wave change, ST elevation/depression, low voltage, AV block, VT/VF); persistent QRS prolongation or AV block portends worse prognosis

SBP <90 + lactate ≥2 + cool extremities → SCAI C+ shock → ROUTE to cardio.cardiogenic-shock.viral-myocarditis.v1; this engine handles SCAI A–B (warm + wet) only

Parvovirus B19, coxsackievirus, enterovirus, adenovirus, HHV-6, SARS-CoV-2, influenza (seasonal additions); guides etiologic differential + adjusts antiviral candidacy

Gold standard noninvasive diagnosis: T2 mapping + edema imaging for active inflammation; LGE in non-ischemic pattern (mid-wall, subepicardial — distinguishes from CAD); native T1 mapping for diffuse fibrosis; LGE persistence at follow-up MRI portends worse prognosis (Mahrholdt PMID 16847141)

These specific etiologies have dedicated treatment (immunosuppression for giant cell/sarcoid; steroids ± targeted therapy for eosinophilic) and route to dedicated dossiers; identification triggers EMB for definitive diagnosis per Cooper 2007 IB criteria

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningprogression_to_fulminant_viral_myocarditis_requiring_shock_pathway
    Hemodynamic deterioration to SCAI C+ shock physiology (SBP <90 + lactate ≥2 + cool extremities + organ dysfunction) — fulminant viral myocarditis requires MCS evaluation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsustained_vt_or_high_grade_av_block_during_acute_myocarditis
    Sustained VT, VF, or high-grade AV block (Mobitz II, complete heart block) during acute viral myocarditis — proarrhythmic substrate from active inflammation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveregdmt_intolerance_during_active_inflammation_phase
    Cannot tolerate GDMT initiation/up-titration due to hypotension, bradycardia, AKI, or hyperkalemia during active myocarditis inflammation phase
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecovid_mis_a_overlap_in_adult_with_viral_myocarditis
    COVID-19 myocarditis with multi-system involvement (rash, conjunctivitis, GI symptoms, shock, multi-organ failure) suggesting MIS-A overlap (multi-system inflammatory syndrome in adults)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveretransplant_listing_decision_for_persistent_severe_dysfunction
    Persistent severe LV dysfunction (EF <25) at 6+ mo despite optimized GDMT + 4-pillar maximally tolerated → transplant listing eligibility decision
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Viral cardiomyopathy / acute viral myocarditis ADHF (non-shock) — supportive ADHF + cautious GDMT + AVOID NSAIDs (ESC 2013 PMID 23824828; AHA 2020 PMID 32200645; 2022 ACC/AHA HF PMID 35363499)
axis: viral_cardiomyopathy_decompensation_phenotype
Selected axis "Viral cardiomyopathy / acute viral myocarditis ADHF (non-shock) — supportive ADHF + cautious GDMT + AVOID NSAIDs (ESC 2013 PMID 23824828; AHA 2020 PMID 32200645; 2022 ACC/AHA HF PMID 35363499)" by default fallback (first axis)
  • furosemide
    first line
    loop_diuretic
    40-80 mg IV (diuretic-naive); 2.5x outpatient PO dose IV if on chronic loop (DOSE-trial guided) • IV • q12h titrate
    triggers: volume_overload_with_pulmonary_or_systemic_congestion
    DOSE PMID 21366472 — high-dose IV bolus or continuous infusion equivalent; titrate to UOP + symptom resolution; transition to PO before discharge
    rxcui 4603
  • nitroglycerin
    add on
    organic_nitrate_vasodilator
    5-20 µg/min IV titrate • IV • continuous
    triggers: hypertensive_adhf_with_sbp_above_140_and_congestion
    Preload + modest afterload reduction for hypertensive ADHF; well-tolerated in viral myocarditis with preserved BP; AVOID if SBP <100 or RV-predominant
    rxcui 4917
  • sacubitril_valsartan
    first line
    arni_neprilysin_inhibitor_arb
    24/26 mg PO BID (titrate to 49/51 then 97/103 BID) • PO • BID
    triggers: hfref_post_myocarditis_with_ef_below_40_and_sbp_above_100
    PIONEER-HF PMID 30403955 — in-hospital initiation; PARADIGM-HF — superior to ACEi for HFrEF; 36h washout from ACEi required
    rxcui 1656328
  • carvedilol
    first line
    beta_blocker_nonselective_alpha1
    3.125 mg PO BID titrate • PO • BID
    triggers: hfref_post_myocarditis_after_inflammation_settling_or_chronic_phase
    CAPRICORN PMID 11356436 + COPERNICUS PMID 11386262 — beta-blocker mortality benefit in HFrEF; AHA 2020 myocarditis PMID 32200645 advises CAUTION during ACTIVE inflammation (some experts delay until troponin normalized) but standard initiation acceptable per most contemporary practice
    rxcui 20352
  • spironolactone
    first line
    mineralocorticoid_receptor_antagonist
    12.5-25 mg PO daily • PO • daily
    triggers: hfref_post_myocarditis_with_ef_below_35_and_k_below_5_and_egfr_above_30
    RALES PMID 10471456 — mortality benefit in HFrEF; monitor K + eGFR; renal dose-adjust
    rxcui 9997
  • dapagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: hfref_post_myocarditis_with_ef_below_40
    DAPA-HF PMID 31535829 — mortality + HF hospitalization benefit; 4th pillar GDMT; safe in active myocarditis (no signal for harm)
    rxcui 1488564
  • empagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: adhf_in_hospital_initiation_per_empulse
    EMPULSE PMID 35347356 — in-hospital initiation safe + improves clinical benefit; alternative to dapagliflozin
    rxcui 1545653
  • amiodarone
    comorbidity specific
    class_iii_antiarrhythmic
    150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h • IV • continuous bolus + infusion
    triggers: sustained_vt_in_active_myocarditis, persistent_afib_with_rvr
    AHA 2020 ACLS — class IIb for sustained VT; preferred over class I antiarrhythmics in inflamed myocardium (class I proarrhythmic in scarred tissue); transition to PO 200 mg daily for chronic suppression
    rxcui 703
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg PO daily INR target 2-3 • PO • daily
    triggers: lv_thrombus_on_echo_post_severe_lv_dysfunction, severe_hfref_with_apical_akinesia
    AHA 2022 Class IIa for LV thrombus 3-mo AC; INR monitoring
    rxcui 11289
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg PO BID (or 2.5 mg BID per dose-reduction criteria) • PO • BID
    triggers: afib_post_myocarditis_with_chads_vasc_above_2, lv_thrombus_warfarin_alternative
    ACC/AHA 2023 AFib (PMID 38033089) — DOAC preferred; ARISTOTLE PMID 21870978
    rxcui 1364430
  • oseltamivir
    comorbidity specific
    neuraminidase_inhibitor_antiviral
    75 mg PO BID × 5 d • PO • BID
    triggers: confirmed_or_suspected_influenza_myocarditis_within_48h_symptom_onset
    CDC influenza — within 48h symptom onset; benefit primarily systemic (no proven cardiac-specific benefit but reasonable in fluA/B-associated myocarditis)
    rxcui 259275
  • remdesivir
    comorbidity specific
    nucleotide_analogue_antiviral
    200 mg IV load × 1 then 100 mg IV daily × 4 d • IV • daily
    triggers: covid19_associated_myocarditis_within_severity_window_per_idsa
    IDSA COVID-19 — no proven cardiac-specific benefit but reasonable in COVID + cardiac involvement; weigh systemic benefit per current IDSA
    rxcui 2284718

outpatient playbook — drug actions (4)

  1. 1. continue 4-pillar GDMT at maximum tolerated
    rxcui 1656328
    sacubitril-valsartan + carvedilol + spironolactone + SGLT2i at goal • PO • as scheduled
    trigger: HFrEF maintenance
    2022 ACC/AHA HF Class I
  2. 2. continue AC if indicated
    rxcui 1364430
    apixaban or warfarin • PO • BID or daily
    trigger: AFib or persistent LV thrombus
    ACC/AHA 2023
  3. 3. discontinue thrombus AC at 3-6 mo if thrombus resolved
    rxcui 1364430
    discontinue per repeat echo at 3-6 mo • PO • discontinue
    trigger: thrombus resolved on follow-up echo
    AHA 2022 Class IIa — 3 mo for LV thrombus then reassess
  4. 4. maintain influenza + COVID vaccination
    annual flu + COVID booster per CDC • IM • annual + per CDC
    trigger: post-myocarditis maintenance
    CDC + AHA 2020 — vaccinations when clinically stable; mRNA COVID vaccines reasonable post-recovery

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Recent (1–4 wk) viral prodrome (URI, GI, flu-like) followed by new HF symptoms (dyspnea, orthopnea, edema) + LV dysfunction on echo + elevated troponin → suspect acute viral myocarditis pathway; Patient with known chronic dilated cardiomyopathy (DCM) attributed to remote viral myocarditis presenting with new ADHF (worsening edema, weight gain, NYHA III–IV symptoms) — non-shock spectrum; Positive viral PCR (parvovirus B19, coxsackievirus, adenovirus, HHV-6, SARS-CoV-2, influenza) in serum or NP swab + new cardiac dysfunction + troponin elevation.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — viral cardiomyopathy / myocarditis decompensation (non-shock)** (cardio.acute-hf.viral-cardiomyopathy-decompensation.v1).
Scope: Viral cardiomyopathy / myocarditis ADHF (non-shock): viral injury → LV dysfunction + congestion; supportive ADHF management; standard GDMT cautiously; AVOID NSAIDs; identify etiology-altering subsets (giant cell, eosinophilic, sarcoid → separate dossiers); recovery possible especially parvovirus

No severity triggers fired against current inputs.

Plan

Regimen axis: **Viral cardiomyopathy / acute viral myocarditis ADHF (non-shock) — supportive ADHF + cautious GDMT + AVOID NSAIDs (ESC 2013 PMID 23824828; AHA 2020 PMID 32200645; 2022 ACC/AHA HF PMID 35363499)**.
1. furosemide 40-80 mg IV (diuretic-naive); 2.5x outpatient PO dose IV if on chronic loop (DOSE-trial guided) IV q12h titrate (loop_diuretic, first line) — DOSE PMID 21366472 — high-dose IV bolus or continuous infusion equivalent; titrate to UOP + symptom resolution; transition to PO before discharge
2. nitroglycerin 5-20 µg/min IV titrate IV continuous (organic_nitrate_vasodilator, add on) — Preload + modest afterload reduction for hypertensive ADHF; well-tolerated in viral myocarditis with preserved BP; AVOID if SBP <100 or RV-predominant
3. sacubitril_valsartan 24/26 mg PO BID (titrate to 49/51 then 97/103 BID) PO BID (arni_neprilysin_inhibitor_arb, first line) — PIONEER-HF PMID 30403955 — in-hospital initiation; PARADIGM-HF — superior to ACEi for HFrEF; 36h washout from ACEi required
4. carvedilol 3.125 mg PO BID titrate PO BID (beta_blocker_nonselective_alpha1, first line) — CAPRICORN PMID 11356436 + COPERNICUS PMID 11386262 — beta-blocker mortality benefit in HFrEF; AHA 2020 myocarditis PMID 32200645 advises CAUTION during ACTIVE inflammation (some experts delay until troponin normalized) but standard initiation acceptable per most contemporary practice
5. spironolactone 12.5-25 mg PO daily PO daily (mineralocorticoid_receptor_antagonist, first line) — RALES PMID 10471456 — mortality benefit in HFrEF; monitor K + eGFR; renal dose-adjust
6. dapagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, first line) — DAPA-HF PMID 31535829 — mortality + HF hospitalization benefit; 4th pillar GDMT; safe in active myocarditis (no signal for harm)
7. empagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, first line) — EMPULSE PMID 35347356 — in-hospital initiation safe + improves clinical benefit; alternative to dapagliflozin
8. amiodarone 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h IV continuous bolus + infusion (class_iii_antiarrhythmic, comorbidity specific) — AHA 2020 ACLS — class IIb for sustained VT; preferred over class I antiarrhythmics in inflamed myocardium (class I proarrhythmic in scarred tissue); transition to PO 200 mg daily for chronic suppression
9. warfarin 5 mg PO daily INR target 2-3 PO daily (vitamin_k_antagonist, comorbidity specific) — AHA 2022 Class IIa for LV thrombus 3-mo AC; INR monitoring
10. apixaban 5 mg PO BID (or 2.5 mg BID per dose-reduction criteria) PO BID (doac_factor_xa_direct, comorbidity specific) — ACC/AHA 2023 AFib (PMID 38033089) — DOAC preferred; ARISTOTLE PMID 21870978
11. oseltamivir 75 mg PO BID × 5 d PO BID (neuraminidase_inhibitor_antiviral, comorbidity specific) — CDC influenza — within 48h symptom onset; benefit primarily systemic (no proven cardiac-specific benefit but reasonable in fluA/B-associated myocarditis)
12. remdesivir 200 mg IV load × 1 then 100 mg IV daily × 4 d IV daily (nucleotide_analogue_antiviral, comorbidity specific) — IDSA COVID-19 — no proven cardiac-specific benefit but reasonable in COVID + cardiac involvement; weigh systemic benefit per current IDSA

Setting playbook (outpatient) — Long-term cardiology surveillance: serial echo + cardiac MRI for recovery assessment; ICD/transplant decision at 3-6 mo if EF persistently <35; activity clearance after 3-6 mo + normal workup; vaccination + secondary prevention
13. continue 4-pillar GDMT at maximum tolerated sacubitril-valsartan + carvedilol + spironolactone + SGLT2i at goal PO as scheduled — HFrEF maintenance (2022 ACC/AHA HF Class I)
14. continue AC if indicated apixaban or warfarin PO BID or daily — AFib or persistent LV thrombus (ACC/AHA 2023)
15. discontinue thrombus AC at 3-6 mo if thrombus resolved discontinue per repeat echo at 3-6 mo PO discontinue — thrombus resolved on follow-up echo (AHA 2022 Class IIa — 3 mo for LV thrombus then reassess)
16. maintain influenza + COVID vaccination annual flu + COVID booster per CDC IM annual + per CDC — post-myocarditis maintenance (CDC + AHA 2020 — vaccinations when clinically stable; mRNA COVID vaccines reasonable post-recovery)

Non-pharmacologic actions:
- Cardiac rehab maintenance phase
- Activity clearance at 3-6 mo if normal echo + MRI + holter + stress test (per Maron 2015 PMID 26621650)
- ICD evaluation at 3-6 mo if EF persistently <35
- Transplant referral if end-stage despite optimized GDMT
- Family screening NOT routinely indicated unless familial DCM history

AVOID / contraindication checks:
- Avoid_nsaids_in_active_viral_myocarditis (AHA 2020 PMID 32200645 — worse outcomes in animal models + observational data)
- Avoid_class_i_antiarrhythmics_in_active_inflammation (proarrhythmic in inflamed myocardium — flecainide, propafenone, lidocaine bolus contraindicated)
- Cautious_bb_initiation_during_active_inflammation (no RCT but reasonable per AHA 2020 — some delay until troponin normalized; standard initiation acceptable per most contemporary practice)
- No_corticosteroids_routinely_in_viral_myocarditis (TIMIC PMID 19651620 — benefit only in virus negative biopsy subset; harm potential in active viral replication)
- No_routine_ivig_in_adult_viral_myocarditis (IMAC McNamara PMID 11524407 — negative trial; reasonable in pediatric fulminant only)
- Avoid_strenuous_activity_for_3_to_6_months_from_diagnosis (Maron 2015 PMID 26621650 — no competitive sports; risk of fulminant deterioration + arrhythmia)
- Arni_avoid_concurrent_acei_or_arb_36h_washout (PIONEER HF + PARADIGM HF protocol; angioedema risk)
- Sglt2i_hold_if_dka_risk_or_aki (DAPA HF + EMPULSE protocols)
- Warfarin_avoid_active_bleeding_or_pregnancy (AHA 2022)
- Apixaban_avoid_severe_renal_impairment_egfr_below_25 (drug label)
- Amiodarone_baseline_pft_lft_tft_q6mo (pulmonary, hepatic, thyroid toxicity)
- Remdesivir_check_lft_baseline_and_during_therapy (hepatotoxicity)
- Oseltamivir_within_48h_symptom_onset_for_efficacy (CDC influenza)

Monitoring

Regimen monitoring:
- continuous telemetry during admission for arrhythmia surveillance
- daily weight io strict
- daily bmp for diuretic safety and gdmt initiation
- serial troponin trend persistent elevation means ongoing injury
- echo at discharge 3 mo 6 mo for lv recovery assessment
- cardiac mri at 3 to 6 mo if initial lake louise positive (LGE persistence prognostic per Mahrholdt PMID 16847141)
- icd eligibility evaluation at 3 to 6 mo if ef persistently below 35
- activity restriction 3 to 6 mo no competitive sports per maron pmid 26621650
- gdmt titration per strong hf protocol pmid 36356631
- inr q week during warfarin initiation
- monthly lft during amiodarone
- transplant referral if end stage despite optimized gdmt

Setting (outpatient) monitoring:
- Quarterly cardiology + serial echo
- Cardiac MRI at 3-6 mo
- INR if warfarin
- Holter for arrhythmia surveillance

Follow-up plan: Cardiology follow-up at 1–2 wk + 3 mo + 6 mo + 12 mo; serial echo + cardiac MRI at 3–6 mo; ICD evaluation at 3–6 mo if EF persistently <35; transplant referral if end-stage despite optimized GDMT; activity clearance for return-to-play after 3–6 mo + normal echo + MRI + exercise stress test + holter (per Maron 2015 PMID 26621650 sports cardiology)
- Close-out criterion: long-term plan + activity-restriction documented

Monitoring phase: Continuous telemetry (arrhythmia surveillance); daily weight + I/O; daily BMP for diuresis safety + GDMT initiation; serial troponin trend (persistent elevation = ongoing injury); echo at d/c + 3 mo + 6 mo for recovery; cardiac MRI at 3–6 mo if initial positive (LGE persistence prognostic); activity restriction 3–6 mo from diagnosis (no competitive sports per Maron PMID 26621650)

Disposition

Current setting: outpatient — Long-term cardiology surveillance: serial echo + cardiac MRI for recovery assessment; ICD/transplant decision at 3-6 mo if EF persistently <35; activity clearance after 3-6 mo + normal workup; vaccination + secondary prevention

Disposition criteria:
- Long-term continuation; if EF normalized at 6-12 mo (especially parvovirus) → consider GDMT taper trial under cardiology supervision; if persistent HFrEF → indefinite GDMT + ICD

Escalation triggers (move to higher acuity):
- Recurrent ADHF → admission
- Sustained VT → EP + ablation
- EF declining despite GDMT → advanced HF eval + transplant
- New non-cardiac symptoms → consider COVID-related sequelae or other viral reactivation

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Hemodynamic deterioration to SCAI C+ shock physiology (SBP <90 + lactate ≥2 + cool extremities + organ dysfunction) — fulminant viral myocarditis requires MCS evaluation
- [LIFE_THREATENING] Sustained VT, VF, or high-grade AV block (Mobitz II, complete heart block) during acute viral myocarditis — proarrhythmic substrate from active inflammation
- [SEVERE] Cannot tolerate GDMT initiation/up-titration due to hypotension, bradycardia, AKI, or hyperkalemia during active myocarditis inflammation phase

Citations

- ESC 2013 myocarditis position statement (Caforio PMID 23824828) + AHA 2020 myocarditis scientific statement (Tschöpe PMID 32200645) + 2022 ACC/AHA HF Guideline (Heidenreich PMID 35363499) + Lake Louise 2018 (Ferreira PMID 30217631) [PMID:23824828](https://pubmed.ncbi.nlm.nih.gov/23824828/)
- Cited evidence (PMID 32200645) [PMID:32200645](https://pubmed.ncbi.nlm.nih.gov/32200645/)
- Cited evidence (PMID 35363499) [PMID:35363499](https://pubmed.ncbi.nlm.nih.gov/35363499/)
- Cited evidence (PMID 30217631) [PMID:30217631](https://pubmed.ncbi.nlm.nih.gov/30217631/)
- Cited evidence (PMID 30290974) [PMID:30290974](https://pubmed.ncbi.nlm.nih.gov/30290974/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ESC 2013 myocarditis position statement (Caforio PMID 23824828) + AHA 2020 myocarditis scientific statement (Tschöpe PMID 32200645) + 2022 ACC/AHA HF Guideline (Heidenreich PMID 35363499) + Lake Louise 2018 (Ferreira PMID 30217631) — PMID:23824828
  • Cited evidence (PMID 32200645) — PMID:32200645
  • Cited evidence (PMID 35363499) — PMID:35363499
  • Cited evidence (PMID 30217631) — PMID:30217631
  • Cited evidence (PMID 30290974) — PMID:30290974